Two-year results of a randomised trial comparing 4- versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancer

医学 前列腺癌 德诺苏马布 危险系数 乳腺癌 内科学 骨转移 肿瘤科 骨质疏松症 癌症 置信区间
作者
Mark J. Clemons,Michelle Liu,Carol Stober,Gregory R. Pond,Mashari Jemaan Alzahrani,Michael Ong,Scott Ernst,Christopher Booth,Mihaela Mates,Anil Abraham Joy,Olexiy Aseyev,Phillip Blanchette,Lisa Vandermeer,Megan M. Tu,Kednapa Thavorn,Dean A. Fergusson
出处
期刊:Journal of bone oncology [Elsevier BV]
卷期号:30: 100388-100388 被引量:18
标识
DOI:10.1016/j.jbo.2021.100388
摘要

BACKGROUND: We present the 2-year results of a randomised trial comparing 4- versus 12-weekly bone-targeting agents (BTAs) in patients with bone metastases from breast or castration-resistant prostate cancer (CRPC). PATIENTS AND METHODS: Patients with bone metastases from breast or CRPC, who were going to start or were already receiving BTAs, were randomised to 4- or 12-weekly BTA treatment for 2 years. The endpoints were: symptomatic skeletal events (SSE) rates, time to SSEs, toxicity and cost-effectiveness. RESULTS: Of 263 patients (160 breast cancer, 103 CRPC), 133 (50.6%) and 130 (49.4%) were randomised to the 4- and 12-weekly groups, respectively. BTAs included denosumab (56.3%), zoledronate (24.0%) and pamidronate (19.8%). After 2 years, the cumulative incidence rate (95% CI) of SSEs was 32.7% (24.6% to 41.1%) and 28.1% (20.3% to 36.4%) for the 4- and 12-weekly intervention groups respectively. The hazard ratio for time to first SSE was 0.96 (95% CI = 0.63 to 1.47). However, in a post hoc analysis, those patients who had an on-study SSE, there was a small non-statistical increased risk of subsequent SSEs among patients on the 12-weekly dosing arm (HR = 1.14; 95% CI - 0.90-1.44). BTA-related toxicity rates were similar between study arms. A cost-utility analysis showed that 12-weekly BTA is cost-effective from a public payer's perspective. CONCLUSION: These results in addition to those previously reported for de-escalating zoledronate, would support that de-escalation of commonly used BTAs is a reasonable and economically valid treatment option. While not statistically significant, the increase in subsequent SSEs in the 12-weekly arm requires further exploration.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
XHZ完成签到,获得积分10
刚刚
虚心的芷烟完成签到,获得积分10
1秒前
1秒前
小三花妙妙完成签到,获得积分10
2秒前
爱听歌盼海完成签到 ,获得积分10
2秒前
3秒前
鸭鸭发布了新的文献求助10
3秒前
3秒前
sdl完成签到,获得积分10
4秒前
ljs完成签到,获得积分10
4秒前
4秒前
童diedie完成签到,获得积分10
5秒前
Czz发布了新的文献求助10
6秒前
荼蘼发布了新的文献求助30
6秒前
乐乐的应助被忐忑的远望采纳,获得10
6秒前
7秒前
小一完成签到,获得积分20
7秒前
7秒前
Rocky完成签到,获得积分10
7秒前
8秒前
8秒前
缓慢的孱的应助被虚心的向秋采纳,获得10
9秒前
11秒前
李爱国的应助被FGGFGGU采纳,获得10
11秒前
李健的应助被LIU采纳,获得10
11秒前
SciGPT的应助被飘飘采纳,获得10
11秒前
Hello的应助被细腻驳采纳,获得10
11秒前
Aaa__JiAn完成签到,获得积分10
12秒前
12秒前
怪默完成签到,获得积分10
13秒前
专注数据线完成签到,获得积分20
14秒前
qqww2233发布了新的文献求助30
14秒前
15秒前
开放满天发布了新的文献求助10
15秒前
miaomiao完成签到,获得积分10
15秒前
15秒前
16秒前
Abracadabra的应助被chen采纳,获得10
16秒前
17秒前
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175157
求助须知:如何正确求助?哪些是违规求助? 9566975
关于积分的说明 21789458
捐赠科研通 7769647
什么是DOI,文献DOI怎么找? 3431836
关于科研通互助平台的介绍 2556078
邀请新用户注册赠送积分活动 2477241